BRIEF-Harpoon Therapeutics Says On April 23, Delaware Court Issued Memorandum Opinion

Reuters2021-04-26

April 26 (Reuters) - Harpoon Therapeutics Inc :

* HARPOON THERAPEUTICS - ON APRIL 23, DELAWARE COURT ISSUED MEMORANDUM OPINION AWARDING MILLENNIUM THERAPEUTICS $38.2 MILLION IN DAMAGES ON CLAIM AGAINST CO

* HARPOON THERAPEUTICS INC - COURT RULED IN FAVOR OF HARPOON ON MAVERICK'S CLAIMS FOR BREACH OF CONTRACT AND MISAPPROPRIATION OF TRADE SECRETS

* HARPOON THERAPEUTICS INC - COURT DETERMINED THAT CO'S PROTRITAC TECHNOLOGY IS NOT IN A FIELD THAT IS SUBJECT TO A FOUR YEAR NON-COMPETE

Source: [ID: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2130531182?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-04-26 20:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2130531182","market":"us","top_or_hot":-1,"title":"BRIEF-Harpoon Therapeutics Says On April 23, Delaware Court Issued Memorandum Opinion","media":"Reuters","content":"<html><body><p>April 26 (Reuters) - Harpoon Therapeutics Inc   :</p><p>   * HARPOON THERAPEUTICS - ON APRIL 23, DELAWARE COURT ISSUED MEMORANDUM OPINION AWARDING MILLENNIUM THERAPEUTICS $38.2 MILLION IN DAMAGES ON CLAIM AGAINST CO</p><p>   * HARPOON THERAPEUTICS INC - COURT RULED IN FAVOR OF HARPOON ON MAVERICK'S CLAIMS FOR BREACH OF CONTRACT AND MISAPPROPRIATION OF TRADE SECRETS</p><p>   * HARPOON THERAPEUTICS INC - COURT DETERMINED THAT CO'S PROTRITAC TECHNOLOGY IS NOT IN A FIELD THAT IS SUBJECT TO A FOUR YEAR NON-COMPETE</p><p>Source: [ID: Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Harpoon Therapeutics Says On April 23, Delaware Court Issued Memorandum Opinion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Harpoon Therapeutics Says On April 23, Delaware Court Issued Memorandum Opinion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-04-26 20:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>April 26 (Reuters) - Harpoon Therapeutics Inc   :</p><p>   * HARPOON THERAPEUTICS - ON APRIL 23, DELAWARE COURT ISSUED MEMORANDUM OPINION AWARDING MILLENNIUM THERAPEUTICS $38.2 MILLION IN DAMAGES ON CLAIM AGAINST CO</p><p>   * HARPOON THERAPEUTICS INC - COURT RULED IN FAVOR OF HARPOON ON MAVERICK'S CLAIMS FOR BREACH OF CONTRACT AND MISAPPROPRIATION OF TRADE SECRETS</p><p>   * HARPOON THERAPEUTICS INC - COURT DETERMINED THAT CO'S PROTRITAC TECHNOLOGY IS NOT IN A FIELD THAT IS SUBJECT TO A FOUR YEAR NON-COMPETE</p><p>Source: [ID: Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HARP","symbol_name":"Harpoon Therapeutics Inc.","start_time":0,"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2130531182","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2130531182","pubTimestamp":1619440499,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"April 26 (Reuters) - Harpoon Therapeutics Inc   :   * HARPOON THERAPEUTICS - ON APRIL 23, DELAWARE C","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HARP":"Harpoon Therapeutics Inc."},"translate_title":"Harpoon Therapeutics表示，4月23日，特拉华州法院发表了备忘录意见书","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MLND":0.9,"HARP":0.9},"content_text":"April 26 (Reuters) - Harpoon Therapeutics Inc   :   * HARPOON THERAPEUTICS - ON APRIL 23, DELAWARE COURT ISSUED MEMORANDUM OPINION AWARDING MILLENNIUM THERAPEUTICS $38.2 MILLION IN DAMAGES ON CLAIM AGAINST CO   * HARPOON THERAPEUTICS INC - COURT RULED IN FAVOR OF HARPOON ON MAVERICK'S CLAIMS FOR BREACH OF CONTRACT AND MISAPPROPRIATION OF TRADE SECRETS   * HARPOON THERAPEUTICS INC - COURT DETERMINED THAT CO'S PROTRITAC TECHNOLOGY IS NOT IN A FIELD THAT IS SUBJECT TO A FOUR YEAR NON-COMPETESource: [ID: Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2130531182","isCrawlerRequest":true}